Adoptive T-cell therapy is one potentially groundbreaking treatment for cancer that genetically alters natural T cells to make them tumor-specific and to improve their ability to destroy tumor cells. The genetically modified T cells are able to express chimeric antigen receptors (CARs) or T-cell receptors (TCRs), showing impressive results in multiple clinical trials.
“T-cell receptor-engineered T-cell therapy” and “Chimeric antigen receptor T-cell therapy” are 2 types of adoptive T-cell therapy that genetically modify natural T cells to treat cancers. Albeit chimeric antigen receptor T-cell therapy has yielded remarkable efficacy for hematological malignancies of the B-cell lineages, most solid tumors fail to respond significantly to chimeric antigen receptor T cells. T-cell receptor-engineered T-cell therapy, on the other hand, has shown promise in treating solidtumors and has attracted growing interest.
The TCR-Executive Report will help you
—In canvassing the field for thoughts on the challenges and opportunities associated with TCR therapeutic space.
—Building a picture of the dynamics of the market, investigating the strategies that key players have or are planning to employ with regards to an access landscape/potential trend.
—Dynamic map of the development landscape and current market landscape, Opportunities, Threats, Players, Partnerships and Treatment and Development Guidelines
There are over 30 active companies that deal with Adoptive TCR-T cell therapy. Out of total active companies, there are over 10 leading companies with over 90 products active in different clinical stages of development. Several important players such as Gilead Sciences, Takara Bio, Cell Medica, Immunocore, Medigene, Immatics US and others are involved in the pipeline.
In addition, various academic institutions such as the National Cancer Institute (NCI) and the National Institutes of Health (NIH) are involved in the development of TCR-T cell therapy. For the past few years, various companies and institutes have been collaborating for the development of the TCR-T cell therapies. There are many emerging companies in the TCR-T cell therapy segment that are looking for collaborative development opportunities to maximize their technology and business platform.
A Sample of Companies Collaborations